230 related articles for article (PubMed ID: 31070067)
1. Potential of NK cells in multiple Myeloma therapy.
Khan AM; Devarakonda S; Bumma N; Chaudhry M; Benson DM
Expert Rev Hematol; 2019 Jun; 12(6):425-435. PubMed ID: 31070067
[No Abstract] [Full Text] [Related]
2. Natural killer cell immunotherapy against multiple myeloma: Progress and possibilities.
Liu P; Jin Y; Sattar H; Liu H; Xie W; Zhou F
J Leukoc Biol; 2018 May; 103(5):821-828. PubMed ID: 29733502
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs.
Festuccia M; Martino M; Ferrando F; Messina G; Moscato T; Fedele R; Boccadoro M; Giaccone L; Bruno B
Expert Opin Biol Ther; 2015 Jun; 15(6):857-72. PubMed ID: 25865214
[TBL] [Abstract][Full Text] [Related]
4. NK cell therapy in relapsed refractory multiple myeloma.
Roshandel E; Ghaffari-Nazari H; Mohammadian M; Salimi M; Abroun S; Mirfakhraie R; Hajifathali A
Clin Immunol; 2023 Jan; 246():109168. PubMed ID: 36415020
[TBL] [Abstract][Full Text] [Related]
5. Translating the anti-myeloma activity of Natural Killer cells into clinical application.
Fionda C; Stabile H; Molfetta R; Soriani A; Bernardini G; Zingoni A; Gismondi A; Paolini R; Cippitelli M; Santoni A
Cancer Treat Rev; 2018 Nov; 70():255-264. PubMed ID: 30326421
[TBL] [Abstract][Full Text] [Related]
6. Nicotinamide-Expanded Allogeneic Natural Killer Cells with CD38 Deletion, Expressing an Enhanced CD38 Chimeric Antigen Receptor, Target Multiple Myeloma Cells.
Edri A; Ben-Haim N; Hailu A; Brycman N; Berhani-Zipori O; Rifman J; Cohen S; Yackoubov D; Rosenberg M; Simantov R; Teru H; Kurata K; Anderson KC; Hendel A; Pato A; Geffen Y
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139060
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapeutic approaches to treat multiple myeloma.
Roeven MW; Hobo W; Schaap N; Dolstra H
Hum Vaccin Immunother; 2014; 10(4):896-910. PubMed ID: 24335570
[TBL] [Abstract][Full Text] [Related]
8. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.
Shi J; Tricot G; Szmania S; Rosen N; Garg TK; Malaviarachchi PA; Moreno A; Dupont B; Hsu KC; Baxter-Lowe LA; Cottler-Fox M; Shaughnessy JD; Barlogie B; van Rhee F
Br J Haematol; 2008 Dec; 143(5):641-53. PubMed ID: 18950462
[TBL] [Abstract][Full Text] [Related]
9. Adoptive cell therapy in multiple Myeloma.
Vallet S; Pecherstorfer M; Podar K
Expert Opin Biol Ther; 2017 Dec; 17(12):1511-1522. PubMed ID: 28857616
[TBL] [Abstract][Full Text] [Related]
10. Harnessing natural killer cells for the treatment of multiple myeloma.
Clara JA; Childs RW
Semin Oncol; 2022 Feb; 49(1):69-85. PubMed ID: 35125241
[TBL] [Abstract][Full Text] [Related]
11. Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma.
Reina-Ortiz C; Giraldos D; Azaceta G; Palomera L; Marzo I; Naval J; Villalba M; Anel A
Cells; 2022 Jan; 11(3):. PubMed ID: 35159200
[TBL] [Abstract][Full Text] [Related]
12. Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and NK cells.
Bernal M; Garrido P; Jiménez P; Carretero R; Almagro M; López P; Navarro P; Garrido F; Ruiz-Cabello F
Hum Immunol; 2009 Oct; 70(10):854-7. PubMed ID: 19580833
[TBL] [Abstract][Full Text] [Related]
13. NK cells and exercise: implications for cancer immunotherapy and survivorship.
Bigley AB; Simpson RJ
Discov Med; 2015 Jun; 19(107):433-45. PubMed ID: 26175401
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
15. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
16. The role of natural killer cells in immunity against multiple myeloma.
Godfrey J; Benson DM
Leuk Lymphoma; 2012 Sep; 53(9):1666-76. PubMed ID: 22423650
[TBL] [Abstract][Full Text] [Related]
17. PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells.
Guo Y; Feng X; Jiang Y; Shi X; Xing X; Liu X; Li N; Fadeel B; Zheng C
Oncotarget; 2016 Jul; 7(30):48360-48374. PubMed ID: 27356741
[TBL] [Abstract][Full Text] [Related]
18. Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.
Pittari G; Vago L; Festuccia M; Bonini C; Mudawi D; Giaccone L; Bruno B
Front Immunol; 2017; 8():1444. PubMed ID: 29163516
[TBL] [Abstract][Full Text] [Related]
19. Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment.
Motais B; Charvátová S; Walek Z; Hrdinka M; Smolarczyk R; Cichoń T; Czapla J; Giebel S; Šimíček M; Jelínek T; Ševčíková T; Sobotka J; Kořístek Z; Hájek R; Bagó JR
Cells; 2021 Apr; 10(5):. PubMed ID: 33919155
[TBL] [Abstract][Full Text] [Related]
20. Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma.
Tognarelli S; Wirsching S; von Metzler I; Rais B; Jacobs B; Serve H; Bader P; Ullrich E
Front Immunol; 2018; 9():2743. PubMed ID: 30542346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
